Company news

Natera, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Natera Reports Second Quarter 2022 Financial Results

August 3, 2022

Natera Announces Second Quarter 2022 Earnings Conference Call

July 31, 2022

Trifecta Study Establishes New Validation Standard for dd-cfDNA in Kidney Transplant Rejection With Largest Prospective, Multisite, Fully Biopsy-Matched Study

June 28, 2022

Natera Appoints Minetta Liu, M.D. as Chief Medical Officer of Oncology

May 23, 2022

Natera Reports First Quarter 2022 Financial Results

May 4, 2022

Natera Announces First Quarter 2022 Earnings Conference Call

May 1, 2022

Natera Announces Definitive Study to Evaluate the Clinical Utility of Renasight in the Diagnosis and Management of Chronic Kidney Disease (CKD)

April 25, 2022

Natera Adds to Organ Health Medical Affairs Leadership Team

April 5, 2022

Natera Announces Updated Signatera™ MRD Data from CIRCULATE-Japan Presented in Plenary Talk at the Society of Surgical Oncology Conference, and Activation of CIRCULATE-US Trial

March 20, 2022

Natera Achieves Milestone of Enrolling First 1,000 Patients in its BESPOKE CRC Study

March 10, 2022

Natera Reports Fourth Quarter and Full Year 2021 Financial Results

February 23, 2022

Natera Announces Fourth Quarter and Fiscal 2021 Earnings Conference Call

February 16, 2022

Natera to Present Latest Signatera™ MRD Data in Colorectal and Pancreatic Cancers at the ASCO GI Symposium 2022, and Host Special Investor Call

January 18, 2022

Natera Announces Expansion Into Early Cancer Detection and Screening

January 5, 2022

Natera Presents Latest Signatera™ MRD Data in Breast Cancer at SABCS 2021

December 8, 2021

Natera Reports Third Quarter 2021 Financial Results

November 3, 2021

Natera Validates Prospera™ With Quantification in Multi-Site, Prospective Trifecta Study

November 2, 2021

Natera Announces Third Quarter 2021 Earnings Conference Call

October 27, 2021

Natera Expands Organ Health Business With Commercial Launch of the Prospera™ Lung Transplant Assessment Test

October 17, 2021

Natera Announces New Publication Validating Signatera® Velocity Metric to Improve Cancer Management

October 10, 2021

Natera Announces Completion of the Largest Prospective Validation Study of a Commercial Cell-Free DNA Test in Lung Transplantation

October 5, 2021

Natera Releases New Clinical Data at ESMO 2021 in Gastroesophageal Cancer and Uveal Melanoma

September 16, 2021

Natera Launches Prospera™ Kidney with Quantification to Further Improve Test Performance, Demonstrating Commitment to Innovation in Transplantation

September 8, 2021

Natera Announces the Validation and Launch of the Prospera™ Heart Transplant Assessment Test

August 30, 2021

Natera Reports Second Quarter 2021 Financial Results

August 4, 2021

Natera Announces Use of Signatera® as a Companion Diagnostic in GSK's Phase III ZEST Trial for Niraparib in Early-Stage Breast Cancer

August 3, 2021

Natera Announces Second Quarter 2021 Earnings Conference Call

July 28, 2021

Natera Reports Preliminary Second Quarter 2021 Results

July 18, 2021

Natera and BGI Genomics Announce Commercial Launch of the BGI/Natera Signatera Assay in China

June 23, 2021

Natera Awarded Advanced Diagnostic Laboratory Test (ADLT) Status for its Signatera® MRD Test From CMS

June 17, 2021

Natera Announces New Prospera™ Data at the ATC 2021 Virtual Connect Conference

June 3, 2021

Natera Reports First Quarter 2021 Financial Results

May 5, 2021

Natera Announces First Quarter 2021 Earnings Conference Call

April 28, 2021

Natera Implements First Wave of Panorama® AI Improvements With Immediate Impact on Patient Experience and COGS

April 6, 2021

Natera and Tesis Labs Announce Strategic Collaboration on Prenatal Genetic Testing

March 30, 2021

Natera Reports Fourth Quarter and Year 2020 Financial Results

February 24, 2021

Natera Announces Fourth Quarter and Fiscal 2020 Earnings Conference Call

February 17, 2021

Panorama® SMART Study Confirms Market-Leading Performance in Largest Prospective NIPT Trial to Date

February 2, 2021

Natera Files Patent Infringement Suit Against Inivata

January 19, 2021

Natera Appoints Dr. Monica Bertagnolli to its Board of Directors

November 18, 2020

Natera Presents New Data at the 2020 SITC Annual Meeting Highlighting Applications of Personalized ctDNA Testing in Immunotherapy Treatment Monitoring

November 9, 2020

Natera Reports Third Quarter 2020 Financial Results

November 4, 2020

Natera Announces Third Quarter 2020 Earnings Conference Call

October 27, 2020

Natera Announces Prospective Randomized Clinical Trial to Evaluate Palbociclib in Early Stage Breast Cancer Patients Who Test Positive with Signatera™

October 1, 2020

Natera Launches Initiative to Transform the Management of Cancer Patients in Organ Transplantation

September 13, 2020

Natera's Signatera™ MRD Test Receives a Final Coverage Decision from Noridian in Colorectal Cancer

September 10, 2020

Natera Receives Final Medicare Coverage for its Signatera™ MRD Test in Stage II-III Colorectal Cancer

September 2, 2020

Natera Announces Collaboration with Massachusetts General Hospital for a Prospective Randomized Clinical Trial in Early Stage Breast Cancer

August 26, 2020

Natera's Signatera™ Test Receives CE Mark

August 25, 2020

Natera Files Additional Suit Against ArcherDX

August 6, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 19 calls. Every call is listed under its year.

Decks

The 5 newest of 57 decks. Every deck is listed under its year.